HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

Authors

null

Jason W.D. Hearn

University of Michigan, Ann Arbor, MI

Jason W.D. Hearn , Ghada AbuAli , Chad A. Reichard , Chandana A. Reddy , Cristina Magi-Galluzzi , Kai-Hsiung Chang , Rachel Carlson , Laureano J Rangel , Kevin Reagan , Brian Davis , Jeffrey Karnes , Manish Kohli , Donald J Tindall , Eric A. Klein , Nima Sharifi

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer—Prostate, Testicular, and Penile

Sub Track

Epidemiology/Outcomes

Citation

J Clin Oncol 34, 2016 (suppl; abstr 5015)

DOI

10.1200/JCO.2016.34.15_suppl.5015

Abstract #

5015

Poster Bd #

272

Abstract Disclosures

Similar Posters

Poster

2015 ASCO Annual Meeting

<em>HSD3B1</em> and resistance to androgen deprivation therapy in prostate cancer.

HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

First Author: Jason W.D. Hearn

Poster

2015 Genitourinary Cancers Symposium

<em>HSD3B1</em> and resistance to androgen deprivation therapy in prostate cancer.

HSD3B1 and resistance to androgen deprivation therapy in prostate cancer.

First Author: Jason W.D. Hearn

Poster

2019 ASCO Annual Meeting

Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.

Outcomes of men with recurrent M0 prostate cancer who defer androgen deprivation therapy until metastasis.

First Author: Catherine Handy Marshall

Poster

2016 ASCO Annual Meeting

<span>Development and validation of genomic signature to predict ADT treatment failure.</span>

Development and validation of genomic signature to predict ADT treatment failure.

First Author: Jeffrey Karnes